Cellectar Biosciences, Inc. (CLRB) financial statements (2022 and earlier)

Company profile

Business Address 100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments35,70457,16510,61513,25610,00611,4453,858
Cash and cash equivalents35,70457,16510,61513,25610,00611,4453,858
Other undisclosed current assets867774771696933749323
Total current assets:36,57157,94011,38613,95210,93912,1934,181
Noncurrent Assets
Operating lease, right-of-use asset 282349
Property, plant and equipment3443564355432451,4441,728
Long-term investments and receivables757575541   
Long-term investments757575541   
Intangible assets, net (including goodwill)    1,6751,6751,675
Goodwill    1,6751,6751,675
Other noncurrent assets66618121212
Other undisclosed noncurrent assets205      
Total noncurrent assets:6307208651,1021,9323,1313,416
TOTAL ASSETS:37,20258,65912,25115,05412,87115,3257,596
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,8553,4432,6641,5441,8681,416676
Accounts payable1,4151,4291,278612   
Accrued liabilities55377271192   
Employee-related liabilities504850395408   
Other undisclosed accounts payable and accrued liabilities1,8817877203321,8681,416676
Debt  1062389246
Deferred rent credit   33
Derivative instruments and hedges, liabilities   431051274,781
Deferred revenue and credits139  
Other undisclosed current liabilities135120     
Total current liabilities:3,9903,5632,7701,6222,1151,6335,703
Noncurrent Liabilities
Long-term debt and lease obligation166302422 2595
Long-term debt, excluding current maturities      87
Capital lease obligations 258
Operating lease, liability166302422
Liabilities, other than long-term debt   171 147149
Deferred revenue and credits 147149
Deferred rent credit   171
Other undisclosed noncurrent liabilities(166)(302)     
Total noncurrent liabilities:1663024221712152244
Total liabilities:4,1573,8653,1911,7932,1171,7855,947
Stockholders' equity
Stockholders' equity attributable to parent, including:33,04554,7959,05913,26110,75413,5401,650
Preferred stock     876 
Common stock1000000
Additional paid in capital182,560161,534119,592108,32394,10883,45166,256
Accumulated deficit (126,775)(111,681)(97,588)(84,349)(70,787)(64,607)
Other undisclosed stockholders' equity attributable to parent(149,516)20,0361,1482,526996  
Total stockholders' equity:33,04554,7959,05913,26110,75413,5401,650
TOTAL LIABILITIES AND EQUITY:37,20258,65912,25115,05412,87115,3257,596

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Gross profit:   (51)  (204)
Operating expenses(24,131)(15,290)(14,179)(13,280)(13,601)(9,450)(8,554)
Operating loss:(24,131)(15,290)(14,179)(13,331)(13,601)(9,450)(8,758)
Nonoperating income91968692393,2693,263
Investment income, nonoperating7 4362223,2623,668
Interest and debt expense 185   (2)(4)
Net loss:(24,122)(14,909)(14,093)(13,239)(13,562)(6,182)(5,499)
Other undisclosed net income (loss) attributable to parent (185)   24
Net loss attributable to parent:(24,122)(15,094)(14,093)(13,239)(13,562)(6,180)(5,495)
Preferred stock dividends and other adjustments   (2,242)(1,449)  
Net loss available to common stockholders, diluted:(24,122)(15,094)(14,093)(15,481)(15,011)(6,180)(5,495)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(24,122)(14,909)(14,093)(13,239)(13,562)(6,182)(5,499)
Comprehensive loss, net of tax, attributable to parent:(24,122)(14,909)(14,093)(13,239)(13,562)(6,182)(5,499)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: